bluebird bio (BLUE) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

bluebird bio Revenue Highlights

Latest Revenue (Y)

$3.60M

Latest Revenue (Q)

$16.10M

Main Segment (Y)

Product

bluebird bio Revenue by Period

bluebird bio Revenue by Year

Date	Revenue	Change
2022-12-31	$3.60M	-1.77%
2021-12-31	$3.66M	-98.54%
2020-12-31	$250.73M	461.25%
2019-12-31	$44.67M	-18.15%
2018-12-31	$54.58M	54.06%
2017-12-31	$35.43M	475.58%
2016-12-31	$6.16M	-56.28%
2015-12-31	$14.08M	-44.62%
2014-12-31	$25.42M	25.97%
2013-12-31	$20.18M	5835.59%
2012-12-31	$340.00K	-61.45%
2011-12-31	$882.00K	-

bluebird bio generated $3.60M in revenue during NA 2022, up -1.77% compared to the previous quarter, and up 10.15% compared to the same period a year ago.

bluebird bio Revenue by Quarter

Date	Revenue	Change
2024-06-30	$16.10M	-13.31%
2024-03-31	$18.57M	137.08%
2023-12-31	$7.83M	-36.78%
2023-09-30	$12.39M	79.85%
2023-06-30	$6.89M	189.37%
2023-03-31	$2.38M	3740.32%
2022-12-31	$62.00K	-12.68%
2022-09-30	$71.00K	-95.33%
2022-06-30	$1.52M	-21.90%
2022-03-31	$1.95M	21.11%
2021-12-31	$1.61M	-92.92%
2021-09-30	$22.68M	203.49%
2021-06-30	$7.47M	-41.60%
2021-03-31	$12.79M	19.48%
2020-12-31	$10.71M	-44.44%
2020-09-30	$19.27M	-90.31%
2020-06-30	$198.89M	809.71%
2020-03-31	$21.86M	118.70%
2019-12-31	$10.00M	12.20%
2019-09-30	$8.91M	-32.99%
2019-06-30	$13.30M	6.62%
2019-03-31	$12.47M	-35.19%
2018-12-31	$19.24M	66.92%
2018-09-30	$11.53M	46.83%
2018-06-30	$7.85M	-50.80%
2018-03-31	$15.96M	282.85%
2017-12-31	$4.17M	-45.95%
2017-09-30	$7.71M	-53.87%
2017-06-30	$16.72M	144.67%
2017-03-31	$6.83M	340.21%
2016-12-31	$1.55M	-
2016-09-30	$1.55M	-
2016-06-30	$1.55M	3.54%
2016-03-31	$1.50M	1.83%
2015-12-31	$1.47M	11.18%
2015-09-30	$1.32M	-73.20%
2015-06-30	$4.94M	-22.13%
2015-03-31	$6.34M	-0.66%
2014-12-31	$6.39M	0.33%
2014-09-30	$6.37M	0.47%
2014-06-30	$6.33M	-
2014-03-31	$6.33M	-
2013-12-31	$6.33M	-0.78%
2013-09-30	$6.38M	0.81%
2013-06-30	$6.33M	462.02%
2013-03-31	$1.13M	1225.88%
2012-12-31	$85.00K	-
2012-09-30	$85.00K	-
2012-06-30	$85.00K	-
2012-03-31	$85.00K	-

bluebird bio generated $16.10M in revenue during Q2 2024, up -13.31% compared to the previous quarter, and up 676.23% compared to the same period a year ago.

bluebird bio Revenue Breakdown

bluebird bio Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Other Revenue	$858.00K	$812.00K	-	-	-
Product	$2.74M	$2.85M	-	-	-
Royalty And Other Revenue	-	-	$21.08M	-	-
Service	-	-	$114.06M	-	-
License And Royalty	-	-	-	$8.21M	$2.23M
Collaboration Arrangement	-	-	-	$36.47M	$1.60M
Royalty	-	-	-	-	$2.20M

bluebird bio's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (76.15%), and Other Revenue (23.85%).

Quarterly Revenue by Product

Product/Service	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18
Royalty And Other Revenue	$111.00K	$53.00K	$85.00K	$71.00K	$188.00K	$537.00K	$1.53M	$488.00K	$5.36M	$3.99M	$3.50M	$10.86M	-	-	-	-	-	-	-	-
Product	$12.28M	$6.84M	$2.30M	-	$1.33M	$1.41M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Service	-	-	-	-	-	-	$6.31M	$5.31M	$5.92M	$5.52M	$13.35M	$78.36M	$16.83M	-	-	-	-	-	-	-
License And Royalty	-	-	-	-	-	-	-	-	-	-	-	-	$2.73M	$2.84M	$2.33M	$1.74M	$1.29M	$861.00K	-	-
Collaboration Arrangement	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.16M	$6.58M	$11.56M	$11.18M	-	-	-
Royalty	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$800.00K	$600.00K	$400.00K

bluebird bio's latest quarterly revenue breakdown by segment (product or service), as of Sep 23: Product (99.10%), and Royalty And Other Revenue (0.90%).

bluebird bio Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
SRPT	Sarepta Therapeutics	$1.24B	$362.93M
PTCT	PTC Therapeutics	$937.82M	$135.42M
KPTI	Karyopharm Therapeutics	$146.03M	$29.52M
TVTX	Travere Therapeutics	$145.24M	$62.90M
VIR	Vir Bio	$86.18M	$2.38M
YMAB	Y-mAbs Therapeutics	$84.82M	$18.46M
CVAC	CureVac	$52.70M	$12.37M
KRYS	Krystal Biotech	$50.70M	$83.84M
MRSN	Mersana Therapeutics	$36.85M	$12.60M
AGIO	Agios Pharmaceuticals	$26.82M	$8.96M
BLUE	bluebird bio	$3.60M	$16.10M
VKTX	Viking Therapeutics	-	-
MDGL	Madrigal Pharmaceuticals	-	$62.17M
ZNTL	Zentalis Pharmaceuticals	-	-
HEPA	Hepion Pharmaceuticals	-	-

BLUE Revenue FAQ

What is bluebird bio’s yearly revenue?

bluebird bio's yearly revenue for 2022 was $3.6M, representing a decrease of -1.77% compared to 2021. The company's yearly revenue for 2021 was $3.66M, representing a decrease of -98.54% compared to 2020. BLUE's yearly revenue for 2020 was $250.73M, representing an increase of 461.25% compared to 2019.

What is bluebird bio’s quarterly revenue?

bluebird bio's quarterly revenue for Q2 2024 was $16.1M, a -13.31% decrease from the previous quarter (Q1 2024), and a 133.69% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $18.57M, a 137.08% increase from the previous quarter (Q4 2023), and a 680.05% increase year-over-year (Q1 2023). BLUE's quarterly revenue for Q4 2023 was $7.83M, a -36.78% decrease from the previous quarter (Q3 2023), and a 12535.48% increase year-over-year (Q4 2022).

What is bluebird bio’s revenue growth rate?

bluebird bio's revenue growth rate for the last 3 years (2020-2022) was -98.57%, and for the last 5 years (2018-2022) was -93.41%.

What are bluebird bio’s revenue streams?

bluebird bio's revenue streams in c 22 are Other Revenue, and Product. Other Revenue generated $858K in revenue, accounting 23.85% of the company's total revenue, up 5.67% year-over-year. Product generated $2.74M in revenue, accounting 76.15% of the company's total revenue, down -3.89% year-over-year.

What is bluebird bio’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of bluebird bio was Product. This segment made a revenue of $2.74M, representing 76.15% of the company's total revenue.